OraSure Technologies (NASDAQ:OSUR) Lowered to Sell at StockNews.com

StockNews.com lowered shares of OraSure Technologies (NASDAQ:OSURGet Rating) from a hold rating to a sell rating in a research report report published on Tuesday morning.

Several other equities research analysts also recently issued reports on OSUR. Lake Street Capital lowered their price target on OraSure Technologies from $20.00 to $14.00 and set a buy rating for the company in a report on Thursday, January 6th. Citigroup lowered their target price on OraSure Technologies from $15.00 to $12.00 and set a buy rating for the company in a research note on Thursday, February 24th. TheStreet cut shares of OraSure Technologies from a c- rating to a d+ rating in a report on Friday, March 4th. Finally, Zacks Investment Research raised shares of OraSure Technologies from a sell rating to a hold rating in a research report on Tuesday, March 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Hold and a consensus price target of $12.13.

OraSure Technologies stock opened at $6.79 on Tuesday. The firm has a market capitalization of $501.89 million, a price-to-earnings ratio of -21.22 and a beta of -0.36. The company’s 50 day simple moving average is $7.59 and its 200 day simple moving average is $8.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.24 and a quick ratio of 3.46. OraSure Technologies has a fifty-two week low of $6.51 and a fifty-two week high of $13.57.

OraSure Technologies (NASDAQ:OSURGet Rating) last posted its earnings results on Wednesday, February 23rd. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. OraSure Technologies had a negative net margin of 9.84% and a negative return on equity of 5.83%. The company had revenue of $63.57 million for the quarter, compared to analyst estimates of $59.99 million. During the same period last year, the business posted $0.03 earnings per share. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. As a group, analysts predict that OraSure Technologies will post -0.1 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Trust Advisors LP bought a new position in OraSure Technologies in the first quarter valued at $353,000. Royal Bank of Canada grew its holdings in shares of OraSure Technologies by 70.7% in the 2nd quarter. Royal Bank of Canada now owns 18,837 shares of the medical instruments supplier’s stock valued at $191,000 after acquiring an additional 7,799 shares in the last quarter. Morgan Stanley increased its position in shares of OraSure Technologies by 135.2% in the second quarter. Morgan Stanley now owns 541,573 shares of the medical instruments supplier’s stock valued at $5,491,000 after acquiring an additional 311,358 shares during the last quarter. Bank of America Corp DE boosted its position in OraSure Technologies by 6.0% during the second quarter. Bank of America Corp DE now owns 5,278,091 shares of the medical instruments supplier’s stock valued at $53,520,000 after purchasing an additional 300,879 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in OraSure Technologies by 15.3% during the third quarter. Fisher Asset Management LLC now owns 82,622 shares of the medical instruments supplier’s stock valued at $934,000 after purchasing an additional 10,952 shares during the last quarter. Institutional investors own 98.74% of the company’s stock.

About OraSure Technologies (Get Rating)

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Recommended Stories

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.